Biotechnology

Azitra

Azitra released FY2026 Q1 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.253 (forecast USD -0.04)

Azitra released FY2025 Annual Earnings on February 27 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.2479 (forecast USD -2.48)

Azitra released FY2025 Q4 earnings on February 27, 2026 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2043 (forecast USD -0.325)

Azitra released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6713 (forecast USD -0.775)

Azitra released FY2025 9 Months earnings on November 12 (EST), actual revenue USD 0, actual EPS USD -3.4047

Azitra released FY2025 Q2 earnings on August 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.1818 (forecast USD -1.3986)

Azitra released FY2025 Semi-Annual earnings on August 11 (EST), actual revenue USD 0, actual EPS USD -0.4043

Azitra Inc. Annual General Meeting Approves Increase in Common Stock Authorization

Azitra Inc. Reports Safety Data for ATR12-351 Phase 1b Trial

Azitra, Inc. to Present Latest Advances in Therapies

Azitra Inc. to Present ATR-04 Clinical Trial Results at ASCO Annual Meeting

Azitra released FY2025 Q1 earnings on May 13 (EST) with actual revenue of USD 0 and EPS of USD -1.5514

Azitra Announces Q1 Financials and Business Updates

Azitra Announces ATR04-484 Phase 1/2 Clinical Trial

Azitra released FY2024 Q4 earnings on February 24 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.0824 (forecast USD -2.0646)

Azitra released FY2024 annual earnings on February 24 (EST), actual revenue 7.5 K USD (forecast 8 K USD), actual EPS -2.3695 USD (forecast -2.05 USD)

Azitra released FY2024 9-month earnings on November 12 (EST), actual revenue USD 7.5K, actual EPS USD -7.2349

Azitra released FY2024 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.1421 (forecast USD -2.331)

Azitra Administers First Dose in ATR-12 Phase 1B Trial for Netherton Syndrome

Azitra released FY2024 Semi-Annual earnings on August 12 (EST), actual revenue USD 7.5K, actual EPS USD -6.8159

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

AZTR

Earnings Watch

Azitra | 8-K: FY2026 Q1 Revenue: USD 0

SBIO

IBBQ

ARKG

businessinsider

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

iShares Biotechnology ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Azitra GAAP EPS of -$0.25

Azitra reported a Q1 2026 net loss of $3.9 million, with cash and equivalents totaling $10.1 million. R&D expenses were $1.6 million, and G&A expenses were $2.4 million. The company expanded its ATR-04 trial sites and received a new U.S. patent for ATR-12, with topline data expected in H2 2026. The first patient has been dosed in the ATR-04 trial, and preclinical progress for ATR-01 is ongoing. A new cosmeceutical initiative has also been launched, with results anticipated in mid-2026.

TradingView

iShares Global Healthcare

VG Health

Health Care Select Sector SPDR

Azitra reports Q1 2026 net loss $3.9M, cash $10.1M; advances ATR-12, ATR-04 trials

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates | AZTR Stock News

StockTitan

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates | AZTR Stock News

A patent has been granted for ATR-12, a genetically modified strain of S. epidermidis that produces a portion of human LEKTI protein. ATR-12 is under Phase 1b testing for treating Netherton syndrome. The location of this development is BRANFORD, Conn., as of May 6, 2026. Azitra, Inc. (NYSE...) is leading this innovative venture.

Unusual Whales

Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program

Azitra, Inc. (NYSE American: AZTR) announced a poster presentation at ASGCT 2026 showcasing preclinical data for its ATR-01 program aimed at treating ichthyosis vulgaris. The data demonstrate that ATR-01 effectively delivers functional filaggrin, restoring skin barrier integrity. The engineered biotherapeutic candidate, ATR01-616, shows significant reduction in transepidermal water loss and restoration of skin structure in models. CEO Francisco Salva emphasized the program's potential to address the disease's underlying cause and advance towards first-in-human trials. Azitra is also developing other therapies for skin conditions using its proprietary microbial platform.

iShares US Pharma

Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris | AZTR Stock News

Azitra Secures PIPE Financing to Advance Cosmetic Programs

Tip Ranks

Azitra Secures PIPE Financing to Advance Cosmetic Programs

Gold Fields fell 7.12% in pre-market; Azitra fell 7.04% in pre-market; Mangoceuticals rose 66.42% in pre-market; Faraday Future rose 51.63% in pre-market; Firefly Neuroscience rose 24.84% in pre-market

Price Alert

Gold Fields

Pre-market hot trades in US stocks: Gold Fields pre-market down 7.12%; Azitra pre-market down 7.04%

Azitra(AZTR.US)

Azitra | 8-K: FY2026 Q1 Revenue: USD 0

Azitra GAAP EPS of -$0.25

Azitra reports Q1 2026 net loss $3.9M, cash $10.1M; advances ATR-12, ATR-04 trials

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates | AZTR Stock News

Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program

Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris | AZTR Stock News

Azitra Secures PIPE Financing to Advance Cosmetic Programs

Pre-market hot trades in US stocks: Gold Fields pre-market down 7.12%; Azitra pre-market down 7.04%